One week before the big hearing, the FDA tipped its hand — and it's a "no"
The honest read on peptides — recovery, midlife, and beyond. What the evidence supports, what it doesn't, and what's just good marketing.
What are "collagen peptides"?
You've seen them in every menopause and wellness aisle. Collagen peptides are just collagen — the structural protein in your skin, bones, and joints — broken into fragments small enough to absorb when you swallow them. That's the whole idea: eat the building blocks, and in theory your body uses them.
The honest read: this is one of the better-evidenced supplement peptides, especially for skin elasticity and postmenopausal bone density — but "better-evidenced" in supplement-land is a low bar, and the effects are modest, not miraculous. A reasonable add-on, not a replacement for the basics.
One week before the hearing, the FDA showed its hand — and it's leaning no
Ahead of the July 23–24 meeting, the FDA published all seven scientific briefing documents for the peptides under review (BPC-157, KPV, TB-500, MOTS-c, DSIP, Semax, Epitalon) — and across all seven, the agency is proposing NOT to add them to the compounding list. The stated reasons are strikingly consistent: the substances aren't well-characterized, there's little or no human evidence of effectiveness for the proposed (mostly injectable) uses, and there's insufficient human safety data — including unassessed immunogenicity risk.
What this means, honestly. This cuts against the "peptides are about to go mainstream" narrative hard. The political leadership has championed these compounds, but the agency's scientists keep landing on "the human data isn't there." These briefing documents are the clearest signal yet of where the evidence review actually points.
Two crucial caveats, so you don't over-read it. First: this is a proposal to the advisory committee, not a final decision — the committee still meets, votes, and the FDA issues final determinations later. Second, and just as important: a "no" here does not mean these peptides are worthless. It means the human evidence isn't strong enough yet for the FDA to green-light pharmacy compounding. "Not proven" is not the same as "disproven." That distinction is the entire reason this newsletter exists.
What the collagen-peptide evidence actually shows
Collagen sits in an unusual spot: more evidence than most supplement peptides, less than the marketing implies. On the pro side: a well-known long-term study in postmenopausal women found specific collagen peptides increased bone mineral density at the spine and femoral neck versus placebo, and multiple skin studies show modest reductions in wrinkles and improved elasticity after 4–8 weeks. On the tempering side: a 2026 randomized trial of collagen plus calcium and vitamin D in menopausal women found no significant change in bone turnover markers or body composition — a reminder that results aren't uniform. And a glycine-rich collagen sleep study showed reduced night-time awakenings, but in a tiny sample of 13 athletic men — interesting, not conclusive.
The keeper concept: collagen peptides are a genuinely reasonable, low-risk add-on with real (if modest) evidence — better than most of what's marketed to you. But "reasonable add-on" and "will transform your skin/bones" are different claims, and only one is true. Foundation first — protein, weight-bearing exercise, calcium and vitamin D — then collagen as a supporting player.
The peptides worth your attention aren't the ones in the hearing
Notice something about this week's regulatory story: the seven peptides the FDA is reviewing are mostly the recovery/longevity/gray-market names (BPC-157, TB-500, Epitalon). Meanwhile, the peptides with the best evidence for women in midlife are largely the ones that aren't in regulatory limbo — because they're either already FDA-approved or sold as supplements.
The practical hierarchy, honestly: the strongest-evidence options for midlife are the FDA-approved peptide medications (GLP-1s, with the muscle-preservation caveats we covered last issue) and topical GHK-Cu for skin. Collagen peptides are a reasonable supplement-tier add-on. The injectable gray-market peptides generating all the hearing headlines are precisely the ones the FDA just said lack human evidence. So the honest takeaway: the loudest, most-hyped compounds are the least proven for you — and the genuinely useful ones aren't the ones making noise.
Educational, not medical advice. Always consult a qualified clinician before starting, stopping, or changing any treatment. Regulatory details current as of writing and subject to change.
← All issues